Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Date:7/31/2008

om $3.4 million for the second quarter of 2007. G&A expenses increased 37 percent to $7.9 million for the six months ended June 30, 2008, from $5.8 million for the same period in 2007. The increases in G&A expenses for the three months ended June 30, 2008 are due primarily to higher personnel costs and increased costs for the use of consultants. The increases in G&A expenses for the six months ended June 30, 2008 are due primarily to higher stock-based compensation expense and increased personnel costs.

Cash and investment securities as of June 30, 2008 were $75.1 million, compared with $92.6 million at December 31, 2007. Management currently believes the existing cash and investment securities will provide adequate resources to fund the Company's operations at least through the second quarter of 2009.

2008 Goals and Objectives

During the remainder of 2008, we anticipate further important advancements in our picoplatin clinical development program. We intend to:

-- Continue enrolling our pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC and advance it towards our commercial launch, targeted in 2010. This registrational trial of intravenous picoplatin is comparing picoplatin with best supportive care to best supportive care alone and is evaluating overall survival as the primary endpoint. It is being conducted under a Special Protocol Assessment from the U.S. Food and Drug Administration in SCLC patients who are refractory or resistant to platinum- based therapy;

-- Present emerging Phase 2 clinical data from both our CRC and HRPC trials at scientific meetings;

-- Present additional data from our Phase 1 oral picoplatin study at scientific conferences; and

-- Evaluate opportunities to expand picoplatin development in additional tumor types, settings and combinations and prepare picoplatin for commercialization.

Conference Call Details

To participate in today's live 5 PM ET/2
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts (SE) announced that ... at this year’s Microsoft Worldwide Partner Conference that was held in Orlando, Florida. ... Winner for Data Platform services, the 2015 HP and Microsoft “Outstanding Frontline Partner” ...
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... Amini, announces that CEREC technology is now available at CitiDent. CEREC is a ... machinery. In addition to saving time for patients by eliminating the need for ...
(Date:9/4/2015)... ... 2015 , ... Mike Day, a former Navy SEAL who was shot 27 ... Championships in Kona on October 10th. , Mike is running the race to raise ... and the cutting-edge treatments that restore their quality of life. More than ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... of personal humidifying medical devices, announced its only mission and research focus: Water ... Research Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. As a ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program for ... Florida October 9-10, 2015 at the Diplomat Resort & Spa has been announced ... and researchers at the top of their field and will be presenting sessions ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... Awards go to Henry Ford Health System, MSU, ... 2008 Five Michigan researchers whose,work has helped ... research dollars totaling $50,000 through Blue Cross Blue ... Awards., The researchers are from Henry Ford ...
... 2008 Protection against,vaccine-preventable diseases is not only ... clinicians aware of the importance of,complete and timely ... Practice has published a supplement to the April ... your community adequately,protected?, Based on a recently ...
... Characterization of Dry-Patch ... Vaccine -, ... announced it will receive a,cost-reimbursement grant for up to $943,856 from the ... a,patch-based version of the anthrax vaccine., Under the 1-year grant, Iomai ...
... Just Plain Fraudulent Asks Top Acupuncture Physician, ... when you,thought it was safe to get acupuncture ... the right to be shamelessly under qualified. This,time ... ordinary to "cure" asthma,ADD, hot flashes, post-stroke injury, ...
... Two Hospitals in the System - Sentara Heart Hospital ... Beach General Hospital ... - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of real-time ... today announced that Sentara Heart,Hospital(R) in Norfolk, Virginia and ...
... TAMPA, Fla., April 8, 2008 A Tampa-area ... medical reporting,systems that allows physicians to gain approval ... with patients as a result., As medical ... -- making patients wait longer for procedures and,giving ...
Cached Medicine News:Health News:Researchers Able to Continue their Work to Help Patients Thanks to McDevitt Excellence in Research Awards from Blue Cross Blue Shield of Michigan Foundation 2Health News:Adults Need Protection Against Vaccine-Preventable Diseases, Too 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 3Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 4Health News:SNAP! CRACKLE! POP! Untrained Chiropractors Doing Acupuncture! 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 3Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 4
(Date:9/4/2015)... AUSTIN, Texas , Sept. 4, 2015  Luminex ... will present at the Morgan Stanley Global Healthcare Conference ... the Grand Hyatt Hotel in New York ... begin at 11:40 a.m. Eastern time on Friday, September ... be accessed at Luminex Corporation,s website at http://www.luminexcorp.com ...
(Date:9/4/2015)... PUNE, India , September 4, 2015 ... "Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and ... by Technology and by Product - Global Forecast to ... expected to reach USD 2.5 Billion by 2020, growing ... from 2015 to 2020. Browse 139 ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on ... nervous system (CNS) diseases and trauma, announced today that ... treatment of acute migraine attacks, from the specialist healthcare ... the precise cause of migraines is not fully understood, ...
... Cohera Medical, a rapidly growing medical device company, announced today ... 50 Awards. Cohera Medical was recognized as the 2011 Life ... Executive Officer, Patrick Daly, was named Pittsburgh CEO of the ... by the Pittsburgh Technology Council as a company that is ...
Cached Medicine Technology:Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 2Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 3Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 2Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 3
... The C. Difficile Tox A/B II is a ... difficile toxins A and B in fecal specimens. ... highly sensitive results detecting not only the more ... are toxin A-/B+. It's easy to perform, produces ...
... The TOX A/B QUIK CHEK test is a ... and B in fecal specimens. The test uses ... C. difficile and yields >90% sensitivity and >99% ... detects both toxin A and toxin B, the ...
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
Medicine Products: